Can bioabsorbable scaffolds be used in calcified lesions?

Catheterization and Cardiovascular Interventions

Volumn 84, Issue 1, 2014, Pages 48-52

  Basavarajaiah, Sandeep ^a,b   Naganuma, Toru ^a   Latib, Azeem ^a   Colombo, Antonio ^a  

^a EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

intravascular ultrasound; rotablation; vasomotion

Indexed keywords

EVEROLIMUS; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY LESION; ARTICLE; BIORESORBABLE SCAFFOLD; CASE REPORT; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CYTOREDUCTIVE SURGERY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; FRACTIONAL FLOW RESERVE; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERTENSION; INTRAVASCULAR ULTRASOUND; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; ROTATIONAL ATHERECTOMY; STABLE ANGINA PECTORIS; VERY ELDERLY; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CALCINOSIS; CORONARY ARTERY DISEASE; RADIOGRAPHY;

ABSORBABLE IMPLANTS; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CALCINOSIS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 84903519304     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24939     Document Type: Article

References (9)

1. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW,. Four-year clinical follow-up of the absorb everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The absorb trial. EuroIntervention 2012; 7: 1060-1061.
2. Onuma YSP, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R,. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human optical coherence tomography images in the absorb trial. Circulation 2010; 122: 2288-2300.
3. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D,. A bioabsorbable everolimus-eluting coronary stent system (absorb): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
4. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S,. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (absorb): A prospective open-label trial. Lancet 2008; 371: 899-907.
5. Sarno GBN, Onuma Y, Garg S, Brugaletta S, De Winter S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Garcia-Garcia HM, Ormiston JA, Serruys PW,. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using ivus, echogenicity and vasomotion testing at two year follow-up: A patient level insight into the absorb a clinical trial. Int J Cardiovasc Imaging 2012; 28: 51-58.
6. Ormiston JA, Serruys PW,. Bioabsorbable coronary stents. Circ Cardiovasc Interv 2009; 2: 255-260.
7. Windecker S, Juni P,. The drug-eluting stent saga. Circulation 2009; 119: 653-656.
8. Abizaid A, Costa JR Jr,. New drug-eluting stents: An overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 2010; 3: 384-393.
9. Nakamura SDFL, Finci L, Reimers B, Adamian M, Di Mario C, Colombo A,. Focal wall overstretching after high-pressure coronary stent implantation does not influence restenosis. Catheter Cardiovasc Interv 1999; 48: 24-30.